Drug Research

The confidential agreement reached by the NHS and the manufacturer is expected to assist up to 1,600 women annually who have high-risk, triple-negative breast cancer. When combined with chemotherapy, pembrolizumab (trade name Keytruda®) reduces the likelihood of breast cancer...

In recent years, the high cost of gene therapies has emerged as a major barrier to the development of personalised medicines. Most notably, bluebird Bio was forced to pull its blood disorder medicine Zynteglo from the European market after...

As anticipated, Congress swiftly reauthorized four important user fee programmes as part of a bill that was essential to passing in order to continue funding the federal government for another two months. The October 1 deadline for approving a...

Gene therapy remains a topic of fascination to biopharmaceutical dealmakers despite safety worries and opposition from drug regulators, as seen by a recent flurry of deals. Eli Lilly agreed to purchase Akouos, a Boston-based company that develops gene therapies for...

One of the most difficult medical research findings, drug distribution still faces a lot of challenges, including surviving the acidic parts of the stomach, digestive enzymes, and most significantly, the mucus barrier that surrounds the digestive canal. Scientists at...

Deals can be just as significant in the drug development industry as scientific advancements. Without mergers and acquisitions, many of today's most significant pharmaceuticals—from the anti-inflammatory Humira to the life-saving cancer medication Keytruda—might not have come to be. Pharmaceutical M&A...

On October 28th, an advisory board to the European Medicines Agency advised restricting the use of a class of medications for inflammatory diseases due to a known association with side effects like cancer and heart attacks. The group recommended limiting...